Objectives: This study sought to test the hypothesis that hyperpolarization-activated cyclic nucleotide-gated (HCN)-based biological pacing might be improved significantly by hyperpolarizing the action potential (AP) threshold via coexpression of the skeletal muscle sodium channel 1 (SkM1).
INTRODuCTION
Electronic cardiac pacing provides effective treatment for heart block and/or sinus node dysfunction but has shortcomings, including inadequate autonomic modulation, limited battery life, lead fracture, and an association with potentially deleterious cardiac remodeling. 1 In seeking better alternatives, we and others have explored diverse strategies to create biological pacemakers. 1 These strategies have used spontaneously active cells (e.g., derivatives of embryonic stem cells or induced pluripotent stem cells) or pacemaker function-related genes delivered via cell platforms or viral vectors.
Recent efforts have focused on improving gene-based biological pacemakers. However, engineered hyperpolarization-activated cyclic nucleotide-gated (HCN) variants have provided improvements that are subtle (e.g., HCN2 E324A) 2 or excessive (e.g., HCN212). 3 Alternative strategies have included overexpressing calcium-stimulated adenylyl cyclase (AC1) 4 or the dominant negative inward rectifier channel Kir2.1-ΔΔΔ, 5 and the combination strategies of HCN2/AC1 4 or HCN2/Kir2.1-ΔΔΔ. 5 Although these strategies represent substantial improvements, no strategy has achieved the pre-defined optimal outcomes of: 1) basal beating rates of 60 to 90 beats/min; 2) autonomic responsiveness resulting in rate increases to 130 to 160 beats/min; and 3) low to absent dependence on electronic backup pacing. 4, 5 To achieve these optimal parameters, we coexpressed skeletal muscle sodium channel 1 (SkM1) with HCN channel 2 (HCN2). Our rationale was as follows: HCN channels generate inward current that drives the membrane toward threshold for the rapid inward sodium current (I Na ). To reach the threshold for I Na , channel opening must be maximized. We have shown that the SkM1 sodium channel has a more depolarized inactivation versus voltage curve and more rapid recovery kinetics from inactivation than the cardiac sodium channel SCN5A. 6, 7 Thus, SkM1 is expected to provide greater availability of sodium channels during diastole, leading to a more negative threshold potential, improved pacemaker stability, and increased beating rates.
MATERIAlS AND METHODS

Experiments conformed to the Guide for the Care and Use of Laboratory Animals
(National Institutes of Health publication 85-23, revised 1996) and were performed using protocols approved by the Columbia University Institutional Animal Care and Use Committee.
Intact canine studies
Adult mongrel dogs were prepared, anesthetized, and fitted with electronic pacemakers (VVI 35 beats/min) and underwent radiofrequency ablation of the atrioventricular node as described previously. 2 One series of animals was injected in the left bundle branch (LBB) with the appropriate adenovirus construct to obtain the following groups: HCN2 (n=12), including 7 previously reported HCN2/green fluorescent protein (GFP)-treated animals, 8 3 current HCN2/GFP-treated animals, and 2 animals injected with HCN2 plus Figure 1 . HCN2/SkM1-based biological pacemakers exhibit improved function over HCN2 and SkM1, with LBB injection providing superior outcomes to left ventricular myocardial injection. A-C, Summary data for left bundle block (LBB)-injected animals receiving hyperpolarizationactivated cyclic nucleotide-gated channel 2 (HCN2; n=12), skeletal muscle sodium channel 1 (SkM1; n=5 in A and B, n=6 in C), or HCN2/SkM1 (n=6). A, Baseline beating rates on days 3 to 7 were faster in HCN2/SkM1-injected animals than in animals injected with only HCN2 or SkM1(*). B, Mean escape times on days 4 to 7 were shorter in HCN2/SkM1-injected animals than HCN2-injected animals (*). C, Median percentage of electronically stimulated beats calculated over 24-h periods were significantly lower in HCN2/SkM1-injected animals than HCN2-injected animals. On days 4 to 7, electronic backup pacing was eliminated in HCN2/SkM1-injected animals. D-F, Summary data for subepicardially injected animals receiving HCN2 (n=10), SkM1 (n=7), or HCN2/ SkM1 (n=6). D, Mean baseline beating rates. E, Mean escape times. F, Median percentage of electronically stimulated beats. G-I, Summary data pooled for days 5 to 7. G, Baseline beating rates in LBB-injected animals receiving HCN2/SkM1 were faster than in LBB-injected animals receiving either HCN2 or SkM1( †). H, Escape times in LBB-injected animals receiving SkM1 or HCN2/SkM1 were significantly shorter compared with those of the respective subepicardial injections ( ‡). Escape times of HCN2/SkM1-injected animals were significantly shorter than those of the respective HCN2 injections (*). I, Median percentage of electronically stimulated beats was reduced to 0% in LBB-injected animals receiving HCN2/SkM1 and was significantly lower than in LBB-injected animals receiving HCN2 (*) or in subepicardially injected animals receiving HCN2/SkM1( ‡). Note that in panels C, F and I, error bars are presented as interquartile range. * † ‡: P<0.05. empty vector; SkM1/GFP (designated SkM1; n=6); and HCN2/SkM1 (n=6). Outcomes in the HCN2/empty group were comparable to those with HCN2/GFP and were therefore combined into one group designated HCN2. Left thoracotomies were performed on a second series of animals using previously described methods, 6 and adenovirus constructs were injected into 3 left ventricular (LV) anterobasal epicardial sites to obtain the following groups: HCN2/GFP (n=10; designated HCN2), SkM1/GFP (n=7; designated SkM1), and HCN2/SkM1 (n=6). Injections were in close proximity (approximately 4 mm) of one another. The injection site was marked with 2 sutures.
Further experimental details and statistical analysis details are in the Supplementary material of this chapter. Figure 2 . HCN2/SkM1-based biological pacemakers injected into the LBB have faster maximal beating rates than those based on HCN2 or SkM1. A, Maximal pace-mapped beating rates in LBB-injected animals. Maximal beating rates were faster in HCN2/SkM1 than HCN2 and SkM1 groups (+). B, Summary data pooled for days 5 to 7. Maximal pace-mapped beating rates in LBB-injected animals were significantly faster in HCN2/SkM1 versus HCN2 or SkM1(+). HCN2/ SkM1 LBB-injected animals also had significantly faster maximal beating rates than respective subepicardially injected animals ( ‡; subepicardially injected animals: HCN2 n=10, SkM1 n=7, HCN2/SkM1 n=6; LBB-injected animals: HCN2 n=12, SkM1 n=6, HCN2/SkM1 n=6). C-E, Left panels show beating rates for every beat during 8 min surrounding an episode of maximal pacemapped beating rate recorded in LBB-injected animals. Right panels provide tracings of baseline and maximal beating rates of the recordings shown on the left. C, Gradual warm up and cool down in an HCN2-injected animal. D, Baseline bigeminy and stable maximal beating rate in a SkM1-injected animal. E, Stable baseline beating and robust rate acceleration followed by cool down in an animal injected with HCN2/SkM1. Abbreviations as in Figure 1 . + ‡: P<0.05.
RESulTS
Intact animal studies Baseline Function
Biological pacing effectiveness was evaluated in light of baseline heart rates, escape times after overdrive pacing, and percentage time during which the backup electronic pacemaker drove the heart (Figure 1 ). These parameters were compared in animals injected with biological pacemakers into the LBB or LV subepicardium. Electrocardiograms (ECGs) were recorded while animals rested quietly on a table (baseline beating rates). Over 7 days, biological pacemaker function in HCN2/SkM1 LBB-injected animals was superior (i.e., faster basal rates, shorter escape times, and lower percentage of electronically stimulated beats) to that of animals with HCN2 or SkM1 alone and was superior to that of animals with LV subepicardial injection of HCN2/SkM1. Typical baseline ECGs and escape times of LBB-injected animals are shown in Supplementary Figure I 
Autonomic Modulation
Sensitivity to autonomic modulation of pace-mapped rhythms was studied via 24-h ECG recordings. Faster beating rates were reached in HCN2/SkM1 LBB-injected animals than those injected with HCN2 or SkM1 (Figure 2A ). At 5 to 7 days, beating rates were significantly faster in animals that received HCN2/SkM1 into the LBB as compared with subepicardial injection ( Figure 2B ). Typical recordings of maximal beating rates in LBB-injected animals are in Figures 2C, 2D , and 2E.
A detailed analysis of percentage pace-mapped rhythms and their autonomic modulation was performed on the ECG Holter recordings at 5 to 7 days. The percentage of matching pace-mapped beats was significantly higher in HCN2/SkM1 LBB-injected animals (>95% of all beats), requiring less pacemaker backup than the respective HCN2-and SkM1-injected groups (P<0.05; Figure 3A ). The percentage of matching beats in animals that received HCN2/SkM1 into subepicardium was lower (approximately 60%) and did not differ from that of HCN2 and SkM1 control groups. Animals injected with SkM1 alone either into the subepicardium or LBB showed persistent bigeminy or trigeminy in more than 10% of beats, whereas no such arrhythmias were detected in animals injected with HCN2 or HCN2/SkM1 (P<0.05; Figure 3A ). The percentage of electronically paced beats was reduced in the HCN2/SkM1-LBB group to 0% of all beats (P<0.05 vs. respective HCN2 and SkM1 groups; Figure 3A ). The 24-h average rate of pace-mapped rhythms is summarized in Figure 3B , showing a faster rate in HCN2/SkM1-LBB versus the HCN2-LBB and SkM1-LBB groups (P<0.05). These results are consistent with the 5-to 7-day averages of baseline and maximal beating rates reported in Figure 2 . Finally, animals that received HCN2 into the LBB exhibited faster 24-h average beating rates than animals that received HCN2 into the subepicardium (P<0.05; Figure 3B ).
To test whether the changes in beating rate and dependence on backup electronic pacing were consistent with what would be expected based on a normal circadian rhythm, we compared these parameters during 2 h of sleep (2:00 to 4:00 am) with 2 h of feeding and activity (8:00 to 10:00 am). Regardless of injection site, HCN2 and HCN2/SkM1 groups exhibited a significant rate acceleration of pace-mapped rhythms from morning to night (P<0.05; Figure 3C ). During sleep as well as during feeding and activity, pace-mapped rhythms were significantly faster in HCN2/SkM1 LBB-injected animals as compared with those in HCN2-LBB and SkM1-LBB groups (P<0.05; Figure  3C ). Furthermore, both HCN2-LBB and HCN2/SkM1-LBB groups exhibited faster beating rates in the morning than the respective subepicardially injected groups (P<0.05; Figure 3C ). The percentage of electronically paced beats during night and morning is summarized in Figure 3D . Subepicardially or LBB-injected animals that received HCN2 exhibited a lower percentage of electronic pacing in the morning than at night (P<0.05; Figure 3D ).
Poincaré plots of pace-mapped rhythms also demonstrated differences in autonomic modulation as analyzed by heart rate variability (HRV) among animals with the 3 gene constructs injected into the LBB ( Figure 4A ). Quantitative analysis of SD parameters revealed that the level of parasympathetic modulation expressed by short-term variation of heart rates (SD1) was comparable among the 3 groups tested ( Figure 5B, left panel) . Sympathetic modulation, expressed as long-term variation of heart rates (SD2), was significantly reduced (i.e., normalized) in the HCN2/SkM1-LBB group as compared with that of animals LBB-injected with HCN2 (P<0.05; Figure 4B , middle panel). The parasympathetic-sympathetic balance (SD1:SD2 ratio) did not differ among the 3 groups (P>0.05; Figure 5B , right panel). Among the subepicardially injected groups, no significant changes in SD1, SD2, and SD1/SD2 were found.
On the final study day, all animals showed a significant rate acceleration upon intravenous epinephrine administration (1.0 μg/kg/min; P<0.05; Figure 4C ). Furthermore, during epinephrine infusion, animals subepicardially injected with HCN2/SkM1 exhibited faster beating rates than the respective HCN2 group (P<0.05). Similarly, during baseline and during epinephrine infusion, HCN2/SkM1 LBB-injected animals showed significantly faster beating rates than their respective HCN2 or SkM1 groups (P<0.05). Finally, in HCN2/SkM1 LBB-injected animals, beating rates in baseline and epinephrine groups were significantly faster than in subepicardially injected animals (P<0.05).
Isolated tissue studies
Figures 5A and 5B provide representative examples and summary data from isolated tissue experiments conducted on LBB from HCN2-, SkM1-and HCN2/SkM1-injected animals. In normal Tyrode solution, beating rates did not differ among groups. However, when isoproterenol was added, HCN2/SkM1-treated preparations beat faster than the others (P<0.05). With isoproterenol 0.1 μM superfusion maintained, we added tetrodotoxin 0.1 μM, which selectively blocks SkM1 current. 7 Tetrodotoxin significantly slowed the HCN2/SkM1-injected preparations, bringing their beating rates into the same range as the HCN2-injected preparations ( Figure 5B ). This is consistent with a major contribution of SkM1 to the beating rates in the presence of isoproterenol. During superfusion with isoproterenol 0.1 μM, maximum diastolic potential was significantly more depolarized in HCN2-overexpressing tissue than in tissue that did not overexpress HCN2 (P<0.05; Figure 5B ).
To test whether threshold potential shifts negatively in the presence of SkM1, we conducted experiments on dogs in which viral constructs were injected into myocardium. Figures 6A,6B , and 6C provide typical tracings and summary data. Data acquired from the first 9 action potentials (APs) per cycle that were stimulated normally confirmed the functional presence of SkM1 in the SkM1 and HCN2/SkM1 groups ( Figure 6C ). Specifically, as in previous reports, 6, 8 SkM1 overexpression induced an increase in maximal upstroke velocity in the SkM1 and HCN2/SkM1 groups compared with those in the respective noninjected controls and the HCN2-injected group (P<0.05). The 10 th AP was generated with a current pulse that was varied to identify the threshold potential for AP initiation. Threshold was reached at more negative voltages in SkM1-and HCN2/SkM1-injected preparations than in noninjected and HCN2-injected controls (P<0.05).
DISCuSSION
Injecting the pacemaker gene HCN2 together with SkM1 into the LBB has provided a construct that compares favorably with other biological pacemaker strategies reported to date. With the HCN2/SkM1 biological pacemaker, rhythms were generated in more than 95% of the beats, in a canine model with a cardiac rhythm status comparable to that of patients requiring ventricular demand pacing. Baseline beating rates were well within a target range of 60 to 90 beats/min and demonstrated brisk autonomic responsiveness as evidenced by the significant response to the epinephrine infusion and the high level of 24-h HRV. The next step in developing HCN2/SkM1-based biological pacemakers will be to move to a delivery system that generates long-term function. Such a system may be provided by lentiviral vectors or by HCN2/SkM1-overexpressing human mesenchymal stem cells (hMSCs).
SkM1/HCN2 pacemaker function in relation to other approaches
Outcomes for baseline and maximal rates of LBB-implanted HCN2/SkM1-based biological pacemakers compared favorably with results reported for AC1 and various HCN isoforms, mutants, and gene combinations. Rates with AC1, 4 wild-type HCN2, and genetically engineered HCN2-E324A, were consistently slower than with HCN2/ SkM1. 2 Although the HCN2/Kir2.1-ΔΔΔ strategy generated robust pacemaker activity at relatively rapid baseline beating rates (90 to 95 beats/min), dependence on electronic backup pacing was not eliminated. 5 Further concerns of this strategy include the prolongation of repolarization induced by Kir2.1-ΔΔΔ 9 and the unknown degree of autonomic modulation. Although the AC1 strategy shows promise with respect to the high efficiency of pacemaker function (>95% of the beats originated from the injection site), physiological beating rates (approximately 60 beats/min), and high sensitivity to parasympathetic modulation, it also manifested relatively slow maximal beating rates and did not eliminate electronic backup pacing. 4 Moreover, the AC1 strategy elevated cAMP levels which may impact on calcium handling in cells, [10] [11] [12] presenting the potential for unwanted side effects such as triggered activity and calcium overload. Although we did not see such side-effects, 4 they remain concerns. In contrast, the HCN2/SkM1 gene combination induced baseline and maximal beating rates with ranges that we had targeted as optimal for a biological pacemaker. We had previously shown as well that the calcium overload one might fear with a sodium channel construct was not an Figure 4 . Detailed analysis of heart rate variability and response to epinephrine infusion. A, Representative Poincaré plots of pace-mapped beats in 24-h Holter recordings of HCN2, SkM1, and HCN2/SkM1 LBB-injected animals. The middle panel (SkM1-injected animal) also defines SD of instantaneous RR-interval variability (SD1) and SD of long-term continuous RR-interval variability (SD2). B, Summary data of SD1, SD2, and SD1:SD2. Animals that showed <5% of matching beats or persistent bigeminy were excluded from this analysis. Subepicardially injected animals: HCN2 n=9, SkM1 n=6, HCN2/SkM1 n=6; LBB-injected animals: HCN2 n=11, SkM1 n=4, HCN2/SkM1 n=6. C, Summary data on the beating rates at baseline and during epinephrine (Epi) infusion. Subepicardially injected animals: HCN2 n=10, SkM1 n=6, HCN2/SkM1 n=6; LBB-injected animals: HCN2 n=12, SkM1 n=4, HCN2/SkM1 n=6. Abbreviations as in Figure 1 issue here. 6 Finally, favorable pacemaker function as manifested by short escape times and low to absent dependence on electronic backup pacing was also characteristic of HCN2/SkM1 LBB-injected animals.
Autonomic modulation of biological pacemaker function
Autonomic modulation of pacing rates is a potential key advantage of biological over electronic pacing. 8 The extent of autonomic modulation that may be obtained via a biological approach likely depends on the gene construct or the cells used. To facilitate the comparison among the various biological pacemaker strategies, we analyzed several measures of autonomic modulation. First, the average baseline beating rate in the HCN2/SkM1-LBB group was relatively rapid (approximately 80 beats/min; Figure 1 ), and the animals maintained robust rate acceleration, reaching average maximal rates of approximately 130 beats/min (Figure 2) . Furthermore, maximal beating rates always remained within the physiological range, never exceeding 180 beats/min. This outcome is superior to the slower maximal beating rates reported here for HCN2 or SkM1 (Figure 2 ) and elsewhere for AC1 4 in LBB-injected animals, superior to results with injection of HCN2/SkM1 into subepicardium (Figure 2) , and superior to the very rapid maximal rates reported for animals in which the chimera HCN212 and the combination of HCN2/AC1 were both injected into LBB. 3, 4 Second, we investigated the average beating rates comparing a period of rest (2:00 to 4:00 am) with one of physical activity and feeding (8:00 to 10:00 am). We found beating rates in accordance with those expected with a normal response to circadian modulation (Figures 3C and 3D) . We also found the circadian response in the HCN2/SkM1-LBB group to be superior to that in animals with LBB gene transfer of HCN2 or SkM1 and myocardial gene transfer of HCN2/SkM1.
Finally, we investigated sensitivity to parasympathetic and sympathetic modulation via analysis of HRV and infusion of epinephrine. The significant reduction in SD2 in the comparison of HCN2/SkM1-LBB with HCN2-LBB ( Figure 4B , middle panel) might suggest reduced sensitivity to sympathetic modulation in the former. However, this is unlikely given the strong in vitro ( Figure 5 ) and in vivo ( Figure 4C ) responses to isoproterenol and epinephrine, respectively, which indicated more profound sensitivity to sympathetic stimuli in HCN2/SkM1-LBB than HCN2-LBB preparations. It should be noted that in the HCN2-LBB group, accelerations (likely induced by sympathetic stimuli) and decelerations (likely resulting from reduced biological pacemaker function) were frequently observed at rest, when beating rates in the HCN2/SkM1 group were relatively stable. Therefore, it appears likely that sympathetic stimulation during rest in the HCN2/SkM1-LBB group was below the level of that in the HCN2-LBB group, although the 24-h average beating rates in the HCN2/SkM1-LBB group were higher ( Figure 3B ). These data indicated that LBB-injected animals that received HCN2 likely manifested increased sympathetic activity during rest as a result of their slower beating rates. The lower average values found for SD2 in the HCN2/SkM1-LBB group therefore indicated reduced activity of the sympathetic system during rest rather than reduced sensitivity to sympathetic modulation. 13 
Mechanisms underlying pacemaker function based on HCN2/SkM1 gene transfer
The microelectrode experiments on myocardial bundles obtained from subepicardially injected animals demonstrated the effect of SkM1 to move the threshold potential to more negative voltages ( Figure 6 ). This observation is significant because shifting the threshold in this direction would result in AP initiation earlier during phase 4 depolarization of automatic fibers. Although this change in AP threshold likely is a major mechanism by which SkM1 improves pacemaker function, other mechanisms should be considered. For example, SkM1 may help to reduce current-to-load mismatch that is potentially present at the interface between transduced and adjacent nontransduced myocardium. The cardiac sodium channel Na v 1.5 is similarly thought to contribute to pacemaker impulse propagation in the sinoatrial node periphery. 14, 15 Based on our original hypothesis that SkM1 would improve HCN2-based pacemaker function, we expected induction of some degree of pacemaker function originating from the injection site of SkM1 adenovirus. Yet, we also recorded persistent bigeminal rhythms originating from the injection site ( Figure 3A) . The timing of these extra beats at coupling intervals of 300 to 700 ms and their dependence on slow baseline heart rates ( Figure 3D ) is consistent with either early afterdepolarizations 16 or re-entry. 17 That SkM1-associated bigeminy is not attributable to an SkM1 action on repolarization was shown in our earlier studies. 6, 7 Moreover, with the SkM1/HCN2 combination, we saw no bigeminy or other instances of proarrhythmia.
Clinical applicability
We consider clinical applicability with the caveat that the standard for the field is electronic pacing, with its considerable strengths and shortcomings that have been described in detail. 1 Biological pacing is being explored by us and by others as a possible adjunct to/replacement for electronic pacing. However, a great deal remains to be done before clinical testing is in order. Given that framework, what can be said about the approach described here? Gene transfer of HCN2/SkM1 generated robust pacemaker function at beating rates close to physiologically desirable levels. The range of function obtained in the short-term setting of the present study compares favorably to that seen with demand electronic pacing of the ventricle. However, for clinical implementation, the level of function that can be generated stably over much longer terms will be crucial to the success of such an approach. To this end, one logical next step is the use of the HCN2 and SkM1 genes in combination with a long-term viral expression vector such as the lentiviral vector. 18 In contrast, adeno-associated viral vectors cannot support genes the size of SkM1 without further modifications. 19 In addition, we previously reported the use of MSCs for the delivery of HCN2 current to myocardium and fabrication of a cell-based biological pacemaker that functioned stably over 6 weeks. 20 In a different study, we also showed that the SkM1 current can be efficiently delivered to myocardium via the MSC platform. 21 Hence, the MSC platform offers an alternative means of gene delivery. However, MSCs show a tendency to migrate from the injection site, causing a loss of pacemaker function over time. For this reason, ongoing efforts are focused on the encapsulation of MSCs, which, if successful, would generate an attractive delivery vehicle for HCN2 and SkM1 ion channels.
CONCluSIONS
When HCN2/SkM1 was administered to the LBB, pacemaker function was facilitated by the slow depolarizing HCN2 current and the hyperpolarized AP threshold generated by SkM1. This dual gene therapy provided both highly efficient pacing and a brisk autonomic response to degrees that appear superior to those of previously developed gene-or cell-based approaches. Figure 6 . SkM1 overexpression shifts threshold potential (TP) negatively. Action potential (AP) parameters and TP were registered from left ventricular subepicardial preparations isolated from HCN2-, SkM1-, or HCN2/SkM1-injected and noninjected regions. Preparations were paced at a cycle length of 1,000 ms with 2-ms current pulses at double threshold amplitude (S1). A 30-ms test current pulse (S2) of variable amplitude was substituted for every 10th regular pulse. A, Typical train of 9 APs initiated with 2-ms 2× threshold S1 current pulses followed by a 10th AP initiated by a 30-ms suprathreshold current pulse (S2). B, Fast-sweep recordings of typical tracings of 30-ms subthreshold and suprathreshold current pulses in noninjected, HCN2-, SkM1-, and HCN2/SkM1-injected preparations. C, Summary data on AP parameters and TP measurements. APA=action potential amplitude; APD30, APD50, APD90=AP duration to 30%, 50%, and 90% repolarization, respectively; MDP=maximum diastolic potential; V max =maximum upstroke velocity; other abbreviations as in Figure 1 . TP was measured for just above threshold current amplitude. *: P<0.05 versus respective HCN2. †: P<0.05 versus respective noninjected.
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MATERIAlS & METHODS
Adenoviral Constructs
Adenoviral constructs of green fluorescent protein (GFP), mouse HCN2 and rat SkM1, all driven by the CMV promoter, were prepared as described previously. 1, 2 We prepared an empty adenoviral vector as an additional control vector. For consistency with earlier studies, 3 we prepared 3×10 10 fluorescence focus forming units of one vector and mixed this with an equal amount of the other vector in a total volume of 700 μL. We did not use a single vector for delivery because the size of SkM1 (5.5 kb) is too large to combine with HCN2 in a single adenoviral vector.
Animal monitoring procedures
ECG, 24-hour Holter monitoring, pacemaker log record check, and overdrive pacing were performed daily for 7-8 days. For each dog, the percent of electronically induced beats was calculated daily. Endogenous pacemaker activity was suppressed by 30 seconds of electronic pacing at 80 bpm or ~10% above intrinsic rhythm.
Twenty-four hour monitoring was performed via Holter ECG (Rozinn, Scottcare, Glendale, New York, U.S.A.). We calculated maximal beating rates daily from 30-sec strips of a stable rhythm at maximal rate. We performed detailed analysis of the percentages of matching and non-matching beats (using pace-mapped beats at time of implant as a reference), bigeminal, and electronically paced beats, 24hr average beating rate of matching rhythms, and HRV on Holter ECG recordings registered during steady-state gene expression (days 5-7; one day per animal). To analyze circadian variation, we compared the rate of pace-mapped beats and dependence on electronic back-up pacing during sleep (2-4 AM) versus during feeding and physical activity (8) (9) (10) . In the analysis of HRV we calculated the standard deviation (SD) of all pace-mapped beats to assess their instantaneous RR-interval variability (SD1) and the SD of long-term continuous RR-interval variability (SD2).
Statistical Analysis
Data are presented as mean±SEM in cases where data follow a normal Gaussian distribution. Statistical significance was examined by t-test or by two-way ANOVA followed by Bonferroni's post-hoc test. In the following datasets we did not detect a normal Gaussian distribution: % paced (daily pacemaker logs), % non-matching rhythm (Holter), % bigeminy (Holter), % paced (Holter), % paced (morning; pacemaker log). In these cases, data are presented as median and interquartile range. Statistical significance was examined by Kruskal-Wallis one-way ANOVA followed by Dunn's multiple comparison test and Mann Whitney test or Wilcoxon matched-pairs signed rank test. P<0.05 was considered significant.
Beta-adrenergic responsiveness
To evaluate β-adrenergic responsiveness at termination of the study, epinephrine (1.0 μg/kg/min) was infused for 10 minutes as previously reported 3 and maximum rate response of the pace-mapped rhythm was recorded.
Tissue bath studies on lBB preparations
Preparations were placed in a 4-mL chamber perfused with Tyrode's solution (37°C, pH 7.3 to 7.4) at a rate of 12 mL/min and were permitted to beat spontaneously. Tyrode's solution containing isoproterenol (0.001 -0.1µM) followed by isoproterenol plus TTX (0.1µM) were applied respectively. Transmembrane AP signals were acquired as described previously. 4, 5 Tissue bath studies on subepicardial myocardial bundles Seven days after subepicardial adenovirus injection, subepicardial myocardial fascicles (~0.5 mm in diameter, 6-10 mm long) were isolated from the injection sites and from remote sites, 3-4 cm from the injected region. Preparations were mounted in a 2-compartment tissue bath, 6,7 whose compartments were separated by a plastic partition having an opening 0.3-0.6 mm in diameter, permitting each preparation to slide through and fit snugly. Each compartment was independently perfused with Tyrode's solution.
Preparations were driven at a cycle length of 1 sec by current pulses delivered through Ag-AgCl electrodes placed in each compartment. Every 10th regular stimulus was replaced by a 30-ms depolarizing current pulse whose amplitude was gradually increased from subthreshold to threshold levels. Conventional microelectrodes were used to record transmembrane potentials at locations within 0.1-0.2 mm of the partition. Phase 0 upstroke velocity was measured by analog differentiation of the transmembrane potential.
Immunohistochemistry
HCN2 and SkM1 overexpression were validated by immunohistochemistry ( Figure II) using previously described methods. 2, 3 In brief, sections were incubated with antiSkM1 antibody (1:200, Sigma-Aldrich, St Louis, Mo) and anti-HCN2 antibody (1:200, Alomone, Jerusalem, Israel). Antibody bound to target antigen was detected by goat anti-mouse IgG labeled with Cy3 (red fluorescence for SkM1) and goat anti-rabbit IgG labeled with Alexa 488 (green fluorescence for HCN2).
HCN2/SkM1
HCN2
SkM1 Overlay + DAPI Non-injected Figure II . Immunohistochemical staining for HCN2 and SkM1. Positive HCN2 (green) and SkM1 (red) staining was detected in LBB from animals that received the corresponding adenovirus. Nuclei were stained blue using DAPI. Bar represents 50 µm.
